Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;102(1):135-148.
doi: 10.1016/j.mcna.2017.08.010.

Obesity Pharmacotherapy

Katherine H Saunders  1 , Devika Umashanker  2 , Leon I Igel  2 , Rekha B Kumar  2 , Louis J Aronne  2
Affiliations
Review

Obesity Pharmacotherapy

Katherine H Saunders et al. Med Clin North Am. 2018 Jan.

Abstract

Although diet, physical activity, and behavioral modifications are the cornerstones of weight management, weight loss achieved by lifestyle modifications alone is often limited and difficult to maintain. Pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m2 or greater or BMI of 27 kg/m2 or greater with weight-related comorbidities. The 6 most commonly used antiobesity medications are phentermine, orlistat, phentermine/topiramate extended release, lorcaserin, naltrexone sustained release (SR)/bupropion SR, and liraglutide 3.0 mg. Successful pharmacotherapy for obesity depends on tailoring treatment to patients' behaviors and comorbidities and monitoring of efficacy, safety, and tolerability.

Keywords: Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Pharmacotherapy; Phentermine/topiramate; Weight management.

PubMed Disclaimer